大脑脊髓液标记与突触可塑性反应和阿尔茨海默病遗传途径有关
Bjørn-Eivind Kirsebom1,2,3, Johanna Nilsson4, Ellen Vromen5,6
1Department of Neurology, University Hospital of North Norway, Tromsø, 9038, Norway. bjorneivind.kirsebom@gmail.com.
Molecular neurodegeneration
|October 14, 2025
概括
大脑脊髓液 (CSF) 的突触生物标志物揭示了不同的阿尔茨海默病 (AD) 进展途径. 增高的可塑性标记物 (14-3-3蛋白质) 和降低的信号标记物 (NPTX-2) 与认知衰退和AD病理相关.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 遗传学 是一个遗传学.
背景情况:
- 突触损失是阿尔茨海默病 (AD) 认知衰退的关键因素.
- 大脑脊髓液 (CSF) 的生物标志物可以阐明AD异质性和超出粉样β (Aβ) 和病理的进展.
- 识别新药点需要了解这些复杂的疾病机制.
研究的目的:
- 研究突触生物标志物在阿尔茨海默病 (AD) 中的作用.
- 根据粉样β (Aβ) 和病理学来区分疾病机制.
- 探索突触标记,认知功能和大脑结构之间的关联.
主要方法:
- 对17个突触生物标记物的质谱分析,包括神经元中毒素 (NPTX) 和14-3-3蛋白.
- 在两个独立的队列 (DDI和阿姆斯特丹痴呆症队列) 中进行评估,使用纵向认知数据.
- 线性回归和道程序分析生物标志物与Aβ/tau状态,认知障碍和MRI体积的关联.
主要成果:
- 在特定的AD患者群体中观察到14-3-3蛋白的升高和NPTX-2的降低.
- 生物标志物变化与轻度认知障碍 (MCI) 严重程度,口头记忆障碍和中间叶缩相关.
- 升高的14-3-3蛋白和rab GDP解离抑制剂α (GDI-1) 预测了未来的进展和记忆力下降.
- 基因分析揭示了14-3-3基因,GDI1和AD相关途径与突触可塑性有关的联系.
结论:
- 不同的突触标志物概况表明了AD进展的不同机制.
- 在Aβ+/Tau-病例中激发信号标记的减少和在Aβ+/Tau+病例中突触可塑性标记的增加表明了复杂的疾病动态.
- 这些发现突出了AD管理的潜在治疗目标.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
822
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
822


